Multicenter study of serotype distribution of Streptococcus pneumoniae nasopharyngeal isolates from healthy children in the Russian Federation after introduction of PCV13 into the National Vaccination Calendar

Сидоренко, С В; Rennert, Wolfgang; Lobzin, Yuri; Брико, Н. И.; Kozlov, Roman; Namazova-Baranova, Leyla; Tsvetkova, I. A.; Ageevets, Vladimir; Nikitina, E. V.; Ardysheva, Anastasia; Bikmieva, A. V.; Bolgarova, E. V.; Волкова, М. О.; Verentsova, I. V.; Гирина, А.А.; Гордеева, Н. В.; Demko, Irina; Dushchenko, Anna; Евсеева, Г П; Zharkova, Ludmila; Yelistratova, T.A.; Zakharova, J.A.; Ивахнишина, Н. М.; Зубова, Е. С.; Kalinogorskaya, Olga; Klimashina, Alla; Kozeeva, Tatiana; Крапошина, А. Ю.; Кречикова, О И; Mamaeva, Marina; Наговицына, Е Б; Протасова, И. Н.; Семериков, В. В.; Sokolova, N. M.; Соловьева, И. А.; Стрельникова, Н В; Telepneva, Regina; Фельдблюм, И. В.; Холодок, Г Н; Chagaryan, Аida N.; Sheglinkova, Nadezhda

doi:10.1016/j.diagmicrobio.2019.114914

Cited by 18 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Improvement in care could potentially contribute to decline in respiratory mortality rates. At the same time, changes in the epidemiology of pneumococcus, particularly reduction in the carriage of vaccine-type strains in children took place in Russia [2-4]. In the US, virtual disappearance of the winter holiday season bump in pneumonia mortality took place following the introduction of the PCV7 vaccine (Figure 2 in [12]), with that bump prior to the introduction of PCV7 ascribed to the transmission of pneumococcal strains from young children to their grandparents during the holiday season.…”

Section: Discussionmentioning

confidence: 99%

“…Pneumococcal conjugate vaccine (PCV13) was introduced in Russia in 2014, with high uptake in young children reported by 2016 [1]. Serotype replacement compared to carriage data from the pre-PCV13 years was found [2-4], with serotype replacement following pneumococcal vaccination also having taken place in other countries [5,6]. While rates of pneumonia following the introduction of PCV13 in Russia have not decreased, neither in children [1], nor overall [7], one can see a notable decline in the rates of mortality for respiratory causes in the years following the rollout of PCV13 [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Decline in respiratory deaths not associated with influenza in Russia: effect of the introduction of the pneumococcal conjugate vaccine (PCV13), or improvement in care?

Goldstein

2020

Preprint

View full text Add to dashboard Cite

Background. Pneumococcal vaccination (PCV13) for children (as well as older adults) in Russia was introduced in 2014, with no prior PCV7 use. While pneumonia hospitalization rates, both in children and adults didn't decrease in the following years, respiratory mortality rates did decline with time. Moreover, there is a strong association between antibiotic, including multidrug resistance and PCV13 vaccine serotypes for S. pneumoniae in children in Russia, and presence of S. pneumoniae among sepsis cases in Russia during the recent years has been very low. Annual variability in influenza circulation may affect some of the changes in respiratory mortality rates, obscuring the trends in respiratory mortality related to pneumococcal vaccination.Methods. We applied the inference method from our recent study of influenzaassociated mortality in Russia to relate monthly respiratory mortality rates between 09/2010 and 08/2019 to monthly indices of influenza circulation and baseline rates of mortality not associated with influenza, allowing for a potential trend in the baseline rates starting 2015.Results. Baseline rates of respiratory mortality not associated with influenza decreased with time starting from the 2014/15 season (with each season running from September to August), with the 2018/19 baseline rates of respiratory mortality per 100,000 individuals being lower by 12.41 (95% CI (10.6,14.2)) compared to the 2010-2014 period.Conclusions. While improvement in care might have contributed to the reduction in the rates of respiratory mortality not associated with influenza in Russia, the above temporally consistent reduction is compatible with the gradual replacement of vaccine serotypes in the transmission and carriage of S. pneumoniae following the introduction of PCV13. Further work is needed to better understand the impact of PCV13 on the epidemiology of respiratory infections and related mortality in Russia.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Decline in respiratory deaths not associated with influenza in Russia: effect of the introduction of the pneumococcal conjugate vaccine (PCV13), or improvement in care?

Goldstein

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Однако за этот же период охват населения старше 18 лет составил 1,5% (1,8 млн человек). Внедрение пневмококковых вакцин в рутинную практику, а также широкий охват ими населения приводят к увеличению частоты встречаемости «невакцинных» серотипов вследствие формирования индивидуального или популяционного иммунитета [16,[20][21][22].…”

Section: Discussionunclassified

“…Том 21 . №4В настоящее время в России отмечаются первые эффекты влияния ПКВ на популяцию пневмококков -снижение доли «вакцинных» серотипов у детей и рост распространенности ранее не встречавшихся «невакцинных» серотипов S. pneumoniae[16]. Существуют отдельные исследования по эпидемиологии серотипов S. pneumoniae в детской популяции после внедрения ПКВ в Национальный календарь профилактических прививок, однако данные для взрослой популяции очень ограничены[11].На первом этапе выполнялась детекция маркерных генов S. pneumoniae -lytA и cpsA.…”

unclassified

The prevalence of circulating S. pneumoniae serotypes in people older than 18 years: healthy carriers, patients with acute otitis media, community-acquired pneumonia, and invasive pneumococcal infections (epidemiological study «SPECTRUM»)

Muravyev

Chagaryan

Иванчик

et al. 2019

CMAC

View full text Add to dashboard Cite

Objective. To estimate the prevalence of S. pneumoniae serotypes in adults aged of 18 years and older, including healthy carriers and patients with acute otitis media (AOM), community-acquired pneumonia (CAP) and invasive pneumococcal infection (IPI). Materials and Methods. A total of 230 isolates of S. pneumoniae from 10 centers were included in the study from 01.06.2019 to 01.10.2019. Re-identification and typing using real-time PCR with 22 primer pairs were performed in the central laboratory (Institute of Antimicrobial Chemotherapy, Russia). Results. In healthy nasopharyngeal carriers (n = 31), the following serotypes of S. pneumoniae were detected: 19F (29.0%), 6А/В (22.6%), 3 (16.1%), 11A/D and 23F (9.7% each), 23A (6.4%), 14 and 15A/F (3.2% each); PCV-13 and PPV-23 covered 80.6% and 90.3% of those serotypes, respectively. In patients with AOM (n = 18), serotypes were: 3 (16.7%), 11A/D and 6A/B (11.1%, each), 16, 19А, 19F, 23F, 7A/F (5.55%, each); PCV-13 and PPV-23 covered 50% and 61.1% of those serotypes, respectively. Among 166 isolates from patients with CAP, the following serotypes were detected: 3 (12.0%), 19F and 6A/B (10.2%, each), 14 and 11A/D (5.4% each), 15A/F and 23A (4.8% each), 9N/L (4.2%), 18 and 22A/F (2.4% each), 19A and 23F (1.8% each), 16, 9V/A (1.2% each), 4 and 33A/33F/37 (0.6% each), non-vaccine serotypes (30.3%); PCV-13 and PPV-23 covered 45.6% and 57.0% of those serotypes, respectively. Isolates from patients with IPI (n=15) belonged to the following serotypes: 3 (26.7%), 12F, 23F and 9N/L (13.3% each), serotypes 4 and 15A/F (6.7%), non-vaccine serotype – 1 isolate (6.7%); PCV-13 and PPV-23 covered 46.7% and 73.3% of those serotypes, respectively. Conclusions. The majority of S. pneumoniae serotypes in adult population in Russia are included in PPV-23, but not in PCV-13 (primarily due to serotype 11A/D). There was a high PCV-13 and PPV-23 coverage of serotypes from healthy nasopharyngeal carriers. PPV-23 covered more than 60% of clinical isolates, whereas PCV-13 covered less than 60% (AOM – 50.0%, CAP – 45.6%, IPI – 46.7%), thus indicating a potentially lower efficacy of PCV-13 in adult population.

show abstract

“…Of the ∼90 serotypes of S. pneumoniae , approximately 20, including the serogroup 6, are responsible for 80–90% of all pneumococcal infections ( van Dam et al, 1990 ). Serogroup 6 belongs to the most frequently revealed pneumococci worldwide ( Hausdorff et al, 2000 ) and in Russian Federation ( Sidorenko et al, 2020 ). Highly immunogenic conjugates of the S. pneumoniae serotype 6A CP with carrier proteins were prepared already at an early stage of pneumococcal vaccine development ( Chu et al, 1983 ).…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Preliminary Immunological Evaluation of a Pseudotetrasaccharide Related to a Repeating Unit of the Streptococcus pneumoniae Serotype 6A Capsular Polysaccharide

Сухова

Yashunsky

Курбатова

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

2-Aminoethyl glycoside of the pseudotetrasaccharide α-d-Glcp-(1→3)-α-l-Rhap-(1→3)-d-Rib-ol-(5-P-2)-α-d-Galp corresponding to a repeating unit of the Streptococcus pneumoniae type 6A capsular polysaccharide has been synthesized. A suitably protected pseudotrisaccharide α-d-Glcp-(1→3)-α-l-Rhap-(1→3)-d-Rib-ol with a free 5-OH group in the ribitol moiety and a 2-OH derivative of 2-trifluoroacetamidoethyl α-d-galactopyranoside have been efficiently prepared and then connected via a phosphate bridge using the hydrogen phosphonate procedure. Preliminary immunological evaluation of this pseudotetrasaccharide and the previously synthesized pseudotetrasaccharide corresponding to a repeating unit of the capsular polysaccharide of S. pneumoniae serotype 6B has shown that they contain epitopes specifically recognized by anti-serogroup 6 antibodies and are able to model well the corresponding capsular polysaccharides. Conjugates of the synthetic pseudotetrasaccharides with bovine serum albumin were shown to be immunogenic in mice.

show abstract

Multicenter study of serotype distribution of Streptococcus pneumoniae nasopharyngeal isolates from healthy children in the Russian Federation after introduction of PCV13 into the National Vaccination Calendar

Cited by 18 publications

References 31 publications

Decline in respiratory deaths not associated with influenza in Russia: effect of the introduction of the pneumococcal conjugate vaccine (PCV13), or improvement in care?

Decline in respiratory deaths not associated with influenza in Russia: effect of the introduction of the pneumococcal conjugate vaccine (PCV13), or improvement in care?

The prevalence of circulating S. pneumoniae serotypes in people older than 18 years: healthy carriers, patients with acute otitis media, community-acquired pneumonia, and invasive pneumococcal infections (epidemiological study «SPECTRUM»)

Synthesis and Preliminary Immunological Evaluation of a Pseudotetrasaccharide Related to a Repeating Unit of the Streptococcus pneumoniae Serotype 6A Capsular Polysaccharide

Contact Info

Product

Resources

About